Navigation Links
Accuray Reports Financial Results for First Quarter of Fiscal Year 2014

SUNNYVALE, Calif., Nov. 7, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today financial results for the first fiscal quarter ended September 30, 2013.
Results are presented on a GAAP basis, unless otherwise indicated, as the magnitude of purchase accounting amortization was minimal for fiscal year 2013 and is projected to be minimal for fiscal year 2014 and beyond, making GAAP results comparable on a year over year basis and a good measure of the company's performance.

First Quarter and Recent Highlights

  • Continued strong order momentum with gross orders of $63.4 million, an increase of 17% from the first fiscal quarter of 2013.
  • Gross profit margins improve 590 basis points, operating expenses decline 13% and adjusted EBITDA improves $8.1 million, all compared to the prior year first fiscal quarter.
  • Over 100 oral and poster presentations at the 55th annual American Society for Radiation Oncology (ASTRO) meeting reinforcing clinical and quality of life benefits for the CyberKnife® and TomoTherapy® Systems.
  • "We had a strong start to the fiscal year with most elements of our performance being above our expectations, reflecting strong commercial and operational execution.  Orders into backlog are being driven by the actions we have taken to improve our commercial focus and enable growth through improved business processes.  We expect that product revenues will begin to strengthen over the next several quarters as well," said Joshua H. Levine, president and chief executive officer of Accuray.  "Improving gross profit margins along with continued expense control in narrowing our adjusted EBITDA losses puts the business on a strong trajectory to achieve profitability, along with higher revenues."

    "We are enthusiastic about fiscal 2014 and the continued execution improvements which were started in the last fiscal year. Our reaffirmed guidance reflects an anticipation that we will return to year over year growth in revenues while the introduction of an adjusted EBITDA measure places our focus on driving the company to positive cash flow," said Levine.

    Financial HighlightsGross product orders totaled $63.4 million for the first quarter, an increase of $9.3 million or 17% over the first quarter of the prior year and a decrease of $8.2 million or 11% from the immediately preceding quarter.  Net product orders totaled $60.1 million for the first quarter, an increase of $8.5 million or 16% from the first quarter of fiscal 2013, and an increase of $2.0 million or 3% from the immediately preceding quarter.  Ending product backlog of $347.8 million was approximately 18% higher than backlog at the end of the prior year first quarter and 10% higher than the previous quarter.

    During the quarter, 13 units were shipped and 14 were installed, increasing Accuray's worldwide installed base to 706 systems.

    Total revenue reached $76.6 million, representing a decrease of 7% from the prior year first quarter and a decrease of 10% from the immediately preceding quarter. Gross profit margin was 34.5%, comprised of service gross margin of 33.0% and product gross margin of 37.1%. This compares to total gross margin of 28.6% for the first quarter of the prior fiscal year and 32.1% in the fourth quarter of fiscal 2013.

    Operating expenses were $38.8 million, compared with $44.3 million in the first quarter of the prior year and $40.0 million in the immediately preceding quarter. Net loss was ($15.5) million, or ($0.21) per diluted share for the first quarter of 2014, compared to a net loss of ($24.1) million, or ($0.34) per diluted share for the first quarter of the prior year and a net loss of ($18.7) million or ($0.25) per diluted share for the fourth quarter of fiscal year 2013.

    Adjusted earnings before interest, taxes, depreciation, amortization and stock-based compensation ("adjusted EBITDA") for the first quarter of 2014 was a loss of ($3.8) million, compared to a loss of ($11.9) million in the first quarter of 2013, and a loss of ($5.9) million in the immediately preceding quarter.

    Cash, cash equivalents, investments and restricted cash were $164.4 million as of September 30, 2013, a decrease of $12.7 million from June 30, 2013.

    2014 Financial GuidanceAccuray reaffirmed its financial guidance of total revenue for fiscal 2014 of $325 million to $345 million.  This is unchanged from the financial guidance provided on August 27, 2013.

    Additional InformationAdditional information including slides of first quarter highlights, which will be discussed during the conference call, is available in the Investor Relations section of the company's website at

    Earnings Call Open to InvestorsAccuray will host an investment community conference call beginning at 1:30p.m. PT/4:30 p.m. ET today to discuss results and answer questions. Conference call dial-in information is as follows:

  • U.S. callers: (866)515-2909  
  • International callers: (617)399-5123
  • Conference ID Number (U.S. and international): 51185854
  • Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company's website, The webcast will be available on the Company's web site for 14 days following the completion of the call.  In addition, a dial-up replay of the conference call will be available beginning November 7, 2013 at 6:00 p.m. PT/9:00 p.m. ET and ending on November 14, 2013. The replay telephone number is 1-888-286-8010 (USA) or 1-617-801-6888 (International), Conference ID: 70135176.

    Use of Non-GAAP Financial MeasuresThe Company has supplemented its GAAP net loss with a non-GAAP measure of adjusted EBITDA. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the Company and facilitates a more meaningful comparison of results for current periods with previous operating results.  Additionally, it will assist management in analyzing future trends, making strategic and business decisions and establishing internal budgets and forecasts. A reconciliation of non-GAAP adjusted EBITDA to GAAP net loss (the most directly comparable GAAP measure) is provided in the schedule below.

    There are limitations in using this non-GAAP financial measure because it is not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies.  This non-GAAP financial measure should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP and the reconciliations of the non-GAAP financial measure provided in the schedule below.

    About AccurayAccuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit

    Safe Harbor StatementStatements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to continuation of sequential and year over year net bookings or total revenue; momentum in our commercial execution; a trajectory towards profitability; expectation of the continuation of the positive trend in our gross profit margin; continued reductions or maintenance of existing levels of operating expenses. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to: the company's ability to convert backlog to revenue; the success of its worldwide sales and marketing efforts; the success of the adoption of our CyberKnife and TomoTherapy Systems; the extent of market acceptance for the company's products and services; the company's ability to manage its expenses; continuing uncertainty in the global economic environment; and other risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K  which was filed on August 29, 2013, and our other filings with the SEC. 

    Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

    Financial Tables to FollowAccuray IncorporatedConsolidated Statements of Operations(in thousands, except per share data)(Unaudited)Three Months Ended September 30,20132012Net revenue:Products 

    $  29,568$  40,628Services 

    47,07342,120Total net revenue 

    76,64182,748Cost of revenue:Cost of products 

    18,60124,009Cost of services 

    31,56235,063Total cost of revenue 

    50,16359,072Gross profit 

    26,47823,676Operating expenses:Selling and marketing 

    14,45412,889Research and development 

    12,95018,574General and administrative 

    11,36012,842Total operating expenses 

    38,76444,305Loss from operations

    (12,286)(20,629)Other expense, net

    (2,460)(704)Loss before provision for income taxes

    (14,746)(21,333)Provision for income taxes

    787597Loss from continuing operations

    (15,533)(21,930)Loss from discontinued operations attributable to stockholders

    -(2,200)Net loss attributable to stockholders

    $(15,533)$(24,130)Loss per share attributable to stockholdersBasic and diluted - continuing operations

    (0.31)Basic and diluted - discontinued operations

    (0.03)Basic and diluted - net loss

    (0.34)Weighted average common shares used in computing loss per shareBasic and diluted

    74,70071,995  Accuray Incorporated  Consolidated Balance Sheets  (in thousands)  (Unaudited)  September 30,  June 30, 20132013 Assets  Current assets:  Cash, cash equivalents and investments 


    74,397 Restricted cash 


    2,728 Accounts receivable, net of allowance for doubtful accounts 


    55,458 Inventories 


    81,592 Prepaid expenses and other current assets 


    12,595 Deferred cost of revenue 


    9,165Total current assets 


    335,935 Property and equipment, net 


    34,733 Goodwill 


    59,368 Intangible assets, net 


    31,896 Deferred cost of revenue 


    2,149 Other assets 


    11,848Total assets 


    $  475,929 Liabilities and equity  Current liabilities:  Accounts payable 


    5,920 Accrued compensation 


    12,461 Other accrued liabilities 


    22,893 Customer advances 


    17,692 Deferred revenue 


    86,893Total current liabilities 


    155,859 Long-term liabilities:  Long-term other liabilities 


    5,382 Deferred revenue 


    9,085 Long-term debt 


    198,768Total liabilities 


    369,094 Equity:  Common stock and additional paid-in capital 


    424,599 Accumulated other comprehensive income 


    1,882 Accumulated deficit 


    (319,646)Total equity 


    106,835Total liabilities and equity 


    $  475,929  Accuray Incorporated  Reconciliation of GAAP net loss to Adjusted Earnings Before Interest, Taxes, Depreciation,  Amortization and Stock-Based Compensation (Adjusted EBITDA)  (In thousands)  (Unaudited) Three Months Ended September 30,Three Months
    Ended June 30,201320122013 GAAP net loss 

    $ (15,533)$ (24,130)$
    (18,715)Amortization of intangibles (a) 

    2,2023,8292,205Depreciation (b) 

    3,2463,9983,514Stock-based compensation (c) 

    2,1801,7552,097Interest expense, net (d) 

    3,3062,0333,331Provision for income taxes 

    7875971,706 Adjusted EBITDA 

    $   (3,812)$ (11,918)$
    (5,862) (a) consists of amortization of intangibles - developed technology, distributor licenses and backlog  (b) consists of depreciation, primarily on property and equipment  (c) consists of stock-based compensation in accordance with ASC 718  (d) consists primarily of interest income from available-for-sale securities and interest expense associated with our convertible notes 

    SOURCE Accuray Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Related biology technology :

    1. Acquisitions, Clinical Trial Results, Date Extensions and Financial Results - Research Report on Endo, Astex, Auxilium, Accuray, and BioScrip
    2. Accuray Announces First CyberKnife System in South America
    3. Accuray Surpasses 600 Installations Globally
    4. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
    5. Omeros Corporation Reports Third Quarter 2013 Financial Results
    6. Global Positron Emission Tomography Market 2012-2016: Industry Analysis, Size, Share, Growth, Trends and Forecast New Research Report Available at
    7. Global In Vitro Fertilization Market 2012-2016: Industry Analysis, Size, Share, Growth, Trends and Forecast New Research Report Available at
    8. Global Biophotonics Market & OSS BSS Industry 2012-2016 Reports
    9. China Vanadium Catalyst Market for Sulfuric Acid Production in A New Research Available at
    10. Cytos Biotechnology Ltd Reports Third Quarter 2013 Financial Results and Recent Developments
    11. Neurocrine Biosciences Reports Third Quarter 2013 Results
    Post Your Comments:
    (Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased ... of over 5.5 million people each year. Especially those living in larger cities are ... - based in one of the most pollution-affected countries globally - decided to take ...
    (Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
    (Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
    (Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. ... event entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, ... was joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, ...
    Breaking Biology Technology:
    (Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
    (Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
    (Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
    Breaking Biology News(10 mins):